Investigation of the clinical, serological and genetic factors that determine primary non-response, loss of response and adverse drug reactions to Anti-TNF drugs in patients with active luminal Crohn's Disease
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2016
Price : $35 *
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PANTS
- Sponsors Abbott Laboratories
- 20 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 11 Feb 2016 Planned End Date changed from 30 Dec 2015 to 1 Jun 2016, according to the United Kingdom Clinical Research Network record.
- 11 Feb 2016 Accrual to date is 96% according to the United Kingdom Clinical Research Network record.